研发实力始终是维康药业发展的核心驱动力。公司高度重视研发能力建设，邀请诺贝尔化学奖得主迈克 尔·莱维特教授担任首席科学家并成立诺贝尔奖工作站，以此提升研发能力及国际化水平。同时，维康 药业持续整合资源，打造了省级高新技术企业研究开发中心、省级企业技术中心、浙江省院士专家工作 站等一系列高能级研发平台，构筑起领先的创新体系。 研发能力的持续积累，正高效转化为具有市场竞争力的产业成果。根据企业半年报，截至报告期末，公 司玉屏风滴丸产品已获得浙江省高新技术产品证书，枫蓼肠胃康分散片等5款产品被浙江省经信委评为 省级工业新产品，血塞通泡腾片等8款药品被登记为浙江省科学技术成果。 近年来，维康药业积极拓展中药大健康领域，稳步推进灵芝孢子粉（破壁）产品的市场布局，并同步储 备灵芝系列产品，逐步形成企业新的业务增长点，展现出清晰的产品梯队和产业布局，开辟第二增长曲 线。 对于维康药业上半年的业绩表现，有业内人士表示，近两年，医药零售行业普遍出现增长放缓、利润承 压的情况。在此背景下，维康药业主动优化业务结构，剥离从事医药零售业务的全资孙公司。虽然短期 内面临业绩阵痛，但公司的核心竞争优势保持稳健，未来聚焦中药创新，有望逐步 ...

公司充分依托浙江龙泉"中华灵芝第一乡"的核心产地优势，在种植环节建立起"无污染、无添加、无公 害"的高标准质量体系；并借助低温物理超微破壁技术，实现了98%的超高破壁率，显著提升了有效成 分的生物利用度，打造生产工艺竞争壁垒；在销售渠道层面，"线上+线下"协同推进，为产品市场渗透 与销售放量提供了坚实保障。 本报讯 （记者冯思婕）8月27日晚，浙江维康药业股份有限公司（以下简称"维康药业"）发布了2025年 半年度报告。报告期内，公司实现营收1.15亿元，归母净利润-0.64亿元。对于半年度业绩变动，公司在 报告中做出说明，主要系本期销售减少以及上年处置子公司合并减少所致。 对于维康药业上半年的业绩表现，有业内人士表示，近两年，医药零售行业普遍出现增长放缓、利润承 压的情况。在此背景下，维康药业主动优化业务结构，剥离从事医药零售业务的全资孙公司。虽然短期 内面临业绩阵痛，但公司的核心竞争优势保持稳健，未来聚焦中药创新，有望逐步重回成长轨道。 公开资料显示，作为国家高新技术企业，维康药业始终秉承"维系苍生、致力安康"的企业使命，在中药 研发领域拥有多年丰富经验，产品线囊括银黄滴丸、益母草软胶囊、七叶神安分散片等 ...

Core Viewpoint - The company Weikang Pharmaceutical (300878.SZ) has been penalized 16 million yuan due to non-operational fund occupation by its actual controller and violations in information disclosure [2][3][6]. Group 1: Regulatory Actions and Penalties - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Weikang Pharmaceutical and its actual controller Liu Zhongliang for suspected violations of information disclosure [3]. - The CSRC found that from 2020 to 2023, Liu Zhongliang organized and directed the company to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal accounts, constituting non-operational fund occupation [3][5]. - The total penalties include 5 million yuan for Weikang Pharmaceutical, 7 million yuan for Liu Zhongliang, and 4 million yuan for five other executives, totaling 16 million yuan [6]. Group 2: Financial Performance and Issues - Weikang Pharmaceutical has experienced a decline in performance since its listing in August 2020, with consecutive losses in 2023 and 2024 [4][10]. - The net profits from 2021 to 2023 were 97 million yuan, 49 million yuan, and a loss of 9 million yuan, respectively [9]. - In 2024, the company reported a loss of 147 million yuan, with a particularly poor performance in the fourth quarter, where revenue was negative 20 million yuan [10][11]. Group 3: Operational Challenges - The company attributes its declining performance to several factors, including reduced demand for prescription drugs due to changes in medical insurance policies and market conditions, increased competition leading to lower gross margins, and a shift in product promotion strategies [10]. - In 2024, Weikang Pharmaceutical's sales expenses were 201 million yuan, accounting for 57.26% of its revenue, while R&D expenses were only 14 million yuan, representing 4% of revenue, a decrease of 66.85% year-on-year [10]. Group 4: Corporate Governance Changes - Due to the fund occupation issues, two executives left their positions, with Liu Zhongliang resigning as chairman and director in May 2024 [7].